Treatment of B-cells non-Hodgkin lymphomas with combined immunochemotherapy: ability to treatment optimization
The results of two consecutive multicenter clinical trials enrolled 241 patient with childhood mature B-cells non-Hodgkin lymphomas/leukemia are presented. Patients received treatment according B-NHL 2004mab protocol (n = 83) and B-NHL 2010M (n = 158) with combined immunochemotherapy (ICT) in Russia...
Main Authors: | N. V. Smirnova, N. V. Myakova, M. B. Belogurova, O. V. Ryskal, O. E. Nikonova, G. R. Sharapova, A. S. Fedorova, N. A. Grigorieva, A. V. Shamardina, N. I. Ponomareva, D. S. Abramov, D. M. Konovalov, M. E. Dubrovina, A. A. Maschan, E. V. Samochatova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-12-01
|
Series: | Onkogematologiâ |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/163 |
Similar Items
-
THE EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR (ACELLBIA®) IN RHEUMATOID ARTHRITIS AS THE FIRST BIOLOGICAL AGENT: RESULTS OF PHASE III (ALTERRA) CLINICAL TRIAL
by: E. L. Nasonov, et al.
Published: (2017-09-01) -
Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency
by: V. A. Misyurin, et al.
Published: (2015-12-01) -
A Double-Blind, Randomized Comparison Study between Zytux™ vs MabThera® in Treatment of CLL with FCR Regimen: Non-Inferiority Clinical Trial
by: Gholamreza Toogeh, et al.
Published: (2018-04-01) -
Simultaneous Monitoring of Monoclonal Antibody Variants by Strong Cation-Exchange Chromatography Hyphenated to Mass Spectrometry to Assess Quality Attributes of Rituximab-Based Biotherapeutics
by: Fiammetta Di Marco, et al.
Published: (2021-08-01) -
Use of crizotinib for refractory ALK-positive lymphomas
by: L N Shelikhova, et al.
Published: (2017-07-01)